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Gonococcal and nongonococcal urethritis are the most common sexually transmitted
diseases in men. Failure to control these infections is a result of improper treatment of index
cases and their sexual contacts. The proper management of urethritis in men is reviewed.
Sexually transmitted diseases (STDs) are epidemic in the United States [1,2]. Re-
cent publicity has focused on herpes genitalis and the lethal acquired immunodefi-
ciency syndrome (AIDS). Interest in these incurable diseases has overshadowed the
continued importance of more traditional STDs. Urethritis remains the most com-
mon acute manifestation of STD in men. Two million cases of gonorrhea and 2.5
million cases of nongonococcal urethritis (NGU) are estimated to occur annually in
the U.S. [1,2]. Over the last decade, advances have been made in defining the
etiology, epidemiology, and complications of NGU. Despite this progress, many
practitioners still equate all urethral symptoms with gonorrhea and the requisite for
intramuscular penicillin. In a recent editorial, Brandt underscored the immediate
need for well-trained front-line practitioners to "combat the STD epidemic of the
1980's and 1990's" [1]. At present, less than six teaching hours are devoted to STDs
in an average four-year medical school curriculum [1].
The intent of this publication is to review the proper management ofthe male pa-
tient with urethral symptoms. The critical management steps are summarized as
follows:
1. Confirm the presence of urethritis by detecting polymorphonuclear
leukocytes in the urethral exudate.
2. Differentiate gonococcal urethritis (GU) from NGU by Gram stain of
an endourethral specimen.
3. Initiate empiric antibiotic therapy based on Gram stain findings,
likelihood of me;dication compliance, and the probability of antibiotic
resistance or extragenital sites of infection.
4. Trace and treat all sexual contacts of patients with GU or NGU.
5. Document symptom resolution, disappearance of urethral inflamma-
tion, and bacteriologic cure after treatment.
IS URETHRITIS PRESENT?
Dysuria localized to the mid or terminal urethra and spontaneous or expressible
urethral discharge are the hallmarks of urethritis. Less specific symptoms include
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All rights of reproduction in any form reserved.urethral itch and, rarely, urinary frequency and urgency. Urethritis may be asymp-
tomatic, detected only by the presence of pyuria in up to 22 percent of cases [3].
Fever, flank pain, or pain occurring only with ejaculation are not features of
urethritis, but implicate a prostatic or upper urinary tract origin.
In examining the urethra for evidence of inflammation, two points are note-
worthy. First, no moisture is normally expressible from the urethral meatus except
immediately following micturition or during sexual arousal. Second, urination less
than two hours prior to examination may wash away abnormal urethral exudate. In-
deed, in patients with urethritis the amount of detectable urethral exudate has been
demonstrated to increase directly with the interval since micturition [3]. If urethral
symptoms exist without detectable exudate, and recent voiding has occurred, a sec-
ond examination two hours post void may prove fruitful.
Polymorphonuclear leukocytes (PMNs) must be present in a urethral smear
(customarily Gram-stained) to diagnose urethritis. The minimum number of PMNs
that is abnormal is unknown, but greater than 4 PMNs per oil immersion field
(970 x) is considered diagnostic [3]. An adequate specimen for smear is readily ob-
tainable if urethral discharge is spontaneous. In the absence of spontaneous
discharge, the urethra should be milked from the base of the penis toward the glans.
If no exudate is expressible, an endourethral specimen should be obtained with a
narrow-tipped calcium alginate swab inserted at least 1 cm into the urethra. The
swab is then rolled gently over a glass slide for staining; vigorous streaking may
destroy cellular morphology.
Another useful technique for localizing inflammation to the urethra requires the
collection of divided urines for quantitative leukocyte counts. Two urine receptacles
are given to the patient. The first 10 ml of urine is voided into one receptacle (first
voided urine), and the remainder of the void is directed into the second receptacle.
Ten ml of urine is then harvested from the second receptable, and the two 10 ml
specimens are centrifuged and compared under high power (400 x) for leukocytes
in the sediment. Greater than 15 PMNs per high-power field in the first voided urine
sediment, with a lesser number in the second sediment, confirms the presence of
urethritis [4]. Equal numbers of PMNs in both sediments suggests cystitis, pros-
tatitis, or upper urinary tract inflammation. This technique is particularly helpful
when expressible discharge is absent, and adequate endourethral swabbing cannot
be performed.
On occasion, despite urethral complaints, discharge is absent and PMNs cannot
be detected in the urethral smear or urine sediment. Contact with urethral irritants,
such as detergents or spermicides, may be causative. In addition, "venerophobia"
following a new sexual contact may result in excessive scrutiny and misinterpretation
of normal urethral sensations that occur during voiding and ejaculation. In such
cases, reassurance and a follow-up examination are all that are necessary. However,
because objective findings of urethritis may be evanescent, the label of functional
urethral symptoms should be withheld until thorough serial examinations have been
performed [5].
ETIOLOGIES
Once the presence ofurethritis has been confirmed, specific causes should be con-
sidered. A comprehensive list of infectious etiologies of male urethritis is presented
in Table 1. Microorganisms that can be recovered from the urethra, but are not
pathogens (despite earlier claims), include Mycoplasma hominis, Gardnerella
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TABLE 1
Infectious Etiologies of Male Urethritis
% Infectious
Urethritis References
I. Gonococcal Urethritis (GU) 30-50 [6]
II. Nongonococcal Urethritis (NGU) 50-70 [7,8]
No NGU
Chlamydia trachomatis 40-50 [7-9]




Herpes simplex rare [3,8,16]
Candida albicans rare [3,8,16]
Endourethral syphilitic
chancre rare [17]
Condylomata accuminata rare [18]
,Etiologic role controversial
vaginalis, Corynebacterium genitalium and pseudogenitalium, cytomegalovirus,
and coliforms [3,10].
Traditionally, urethritis has been classified as gonococcal or nongonococcal. This
distinction arose because gonococci are readily identifiable by urethral Gram stain
and culture, whereas the agents of NGU are not. Nonspecific urethritis (NSU) is an
obsolete term previously used to describe the 95 percent of NGU not caused by Can-
dida albicans, Trichomonas vaginalis, or Herpes simplex [7]. Since Chiamydia
trachomatis is now known to cause 40-50 percent ofNGU, the term NSU, which im-
plies no specific etiology, should be abandoned.
GONOCOCCAL URETHRITIS
The descriptive term gonorrhea: the "flow of seeds," was coined by the Greek
physician Galen in 130 A.D. More than seventeen centuries later, Neisser dis-
covered the diplococcus that now bears his name. Neisseria gonorrhoeae is a non-
motile, Gram-negative, aerobic bacterium that characteristically grows in pairs or
diplococci (long axis apposed and adjacent sides flattened). The organism causes
30-50 percent of male urethritis. Gonococcal isolation rates are highest (60-70 per-
cent) in urban males oflower socioeconomic status [6]. In contrast, less than 10 per-
cent of urethritis in university students is gonococcal in origin [19]. Other
characteristics ofGU include an abrupt onset ofdysuria and urethral discharge three
to four days after exposure. Discharge is purulent in over 90 percent of cases, and a
spontaneous urethral "drip" occurs in 30-40 percent. For comparison, discharge is
purulent in only 20-25 percent ofNGU, and is rarely spontaneous (< 5 percent) [6].
Despite these suggestive features, GU cannot be reliably distinguished from NGU
on clinical grounds alone. A urethral Gram stain or culture is required. Iftypical, in-
tracellular Gram-negative diplococci (GND) are present on urethral Gram stain, 98
percent of cultures will grow gonococci. When no intra- or extracellular GND are
present, 99 percent of cultures will be negative. Approximately 15 percent of Gram
stains are equivocal, revealing extracellular GND only. Only 10 percent ofequivocal
IIIsmears will be culture-positive. Overall, few diagnostic tests in medicine are as safe,
simple, inexpensive, and accurate as the urethral Gram stain is in symptomatic
urethritis [6]. Accordingly, it should be employed in the diagnostic evaluation of all
patients with urethritis.
A urethral Gram stain that demonstrates intracellular GND warrants treatment of
the patient and his sexual contacts for gonorrhea. Urethral culture is optional unless
Gram stain findings are equivocal or penicillin resistance is suspected. For health
department reporting purposes, a Gram stain diagnosis of GU is sufficient.
Several treatment options for uncomplicated GU exist and are listed in Table 2,
along with specific advantages and disadvantages for each regimen listed [20]. Cure
rates for GU approach 95 percent for all regimens listed [21]. The likelihood of
medication compliance and the probability of extraurethral gonococcal infection
(pharynx or rectum) should influence the antibiotic choice.
For non-compliant patients, single-dose therapy with parenteral penicillin G or
oral amoxicillin/ampicillin is preferable. In the penicillin-allergic, non-compliant
patient, single-dose spectinomycin is the treatment of choice. For compliant pa-
TABLE 2
Treatment Regimens for Uncomplicated Gonococcal Urethritis [20]
(Penicillin-Sensitive N. Gonorrhoeae)
Regimen
(not listed in order of
preference) Advantages Disadvantages
1. Aqueous Procaine 1. Single-dose therapy 1. Painful IM infection
Penicillin G: 2. Effective against anorectal 2. Possible penicillin anaphy-
4.8 million units IM (2 and pharyngeal infection; laxis: 1/10,000 [12]
sites) treatment of choice in 3. Possible procaine reaction
plus homosexual men (psychosis): 1/1,000 [12]
probenecid 1.0 g p.o. 3. Eradicates incubating 4. No activity against con-
syphilis comitant C. trachomatis in-
fection
2. Ampicillin/Amoxicillin: 1. Single-dose therapy 1. Ineffective against ano-
ampicillin 3.5 g p.o. or 2. No injection rectal and pharyngeal
amoxicillin 3.0 g p.o. 3. Eradicates incubating infection
either with syphilis 2. No activity against con-
probenecid 1.0 g p.o. 4. Lower incidence of ana- comitant C. trachomatis
phylaxis vs. IM route infection
3. Tetracycline: 1. Effective against concom- 1. Requires compliance
500 mg p.o. QID for 7 itant C. trachomatis in- 2. Ineffective against ano-
days fection rectal infection in men




4. Spectinomycin: 1. Single-dose therapy for 1. Ineffective against phar-
2.0 g IM penicillin-allergic patient yngeal infection
2. Effective against anorectal 2. No activity against con-
infection comitant C. trachomatis
3. Effective against penicil- infection
linase-producing strains 3. Does not eradicate incu-
(PPNG) bating syphilis
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tients, tetracycline is highly effective and has the unique advantage of preventing
most postgonococcal urethritis (PGU) [12]. Seventeen to 32 percent of patients with
GU are co-infected with C. trachomatis [8,15,22]. When co-infected patients are
treated with an antibiotic other than tetracycline, over 80 percent develop PGU
[8,12]. If initial treatment is with tetracycline, less than 10 percent develop PGU. To
prevent PGU and to insure gonococcal eradication, single-dose anti-gonococcal
therapy with ampicillin/amoxicillin, followed by one week of tetracycline, has been
recommended for widespread use [20]. However, the efficacy and safety of this
combined regimen have not been established.
Homosexual men with GU who practice fellatio and rectal intercourse often have
pharyngeal and rectal gonococcal infection. For these extraurethral sites of infec-
tion, parenteral penicillin G is the most effective regimen. Ampicillin/amoxicillin
and spectinomycin are not effective for pharyngeal infection [23,24], and a 15 per-
cent failure rate has been reported for rectal infection in men treated with
tetracycline [25]. For penicillin-allergic patients with pharyngeal and rectal infec-
tion, nine tablets of trimethoprim-sulfamethoxazole (80 mg/400 mg) as a single daily
dose, for five days, is indicated.
Penicillinase-producing N. gonorrheae (PPNG) was first recognized in 1976
[26-28]. From 1976-1979, fewer than 400 cases were reported annually in the U.S.,
with most cases being acquired in endemic areas in Southeast Asia or West Africa
[29]. Starting in 1980, sustained domestic spread of imported PPNG occurred,
which resulted in a dramatic increase in reported cases from 328 in 1979 to 9,208 in
1982 [CDC: Venereal Disease Control Division]. Currently, PPNG is concentrated
in the indigent populations of large cities: New York, Miami, and San Diego.
Gonococcal infection acquired in a PPNG endemic area or persistent GU after treat-
ment should raise the suspicion of PPNG infection.
Spectinomycin 2.0 g intramuscularly is the treatment of choice for PPNG; only
one well-documented case of spectinomycin resistance has been reported [30].
Limitations of spectinomycin include inadequate activity against pharyngeal PPNG
infection, incubating syphilis, or concomitant C. trachomatis infection. Alternatives
to spectinomycin include cefoxitin 2.0 g intramuscularly plus probenecid 1.0 g by
mouth or cefotaxime 1.0 g intramuscularly without probenecid. As with spec-
tinomycin, neither cefoxitin nor cefotaxime has activity against pharyngeal PPNG
or C. trachomatis infection. Most PPNG are tetracycline-resistant; therefore,
tetracycline must be added to spectinomycin to prevent PGU [31]. For pharyngeal
PPNG infection, trimethoprim-sulfamethoxazole (80 mg/400 mg) nine tablets daily,
for five days, is the only treatment option.
Treatment of all heterosexual and homosexual contacts of men with GU is essen-
tial. In the U.S., gonorrhea has been erratically controlled because treatment of
asymptomatic sexual contacts remains inconsistent. This inconsistency preserves a
vast human reservoir of N. gonorrhoeae and sustains the occurrence of two million
cases annually. Asymptomatic gonococcal infection is not limited to women. Thirty
to 50 percent of male contacts of women with acute pelvic inflammatory disease
have asymptomatic urethral infection, and 20-30 percent of male homosexuals are
rectal gonococcal carriers [32,33]. The only means of reducing carrier and transmis-
sion rates is by widespread empiric treatment of all sexual contacts of index cases.
Once treated, follow-up cultures to detect treatment failure are mandatory. In addi-
tion to a urethral culture, homosexual men should have rectal and pharyngeal
cultures to exclude persistent extragenital infection. For heterosexual women, cer-




Chlamydiae are unique, tetracycline-sensitive, bacterial pathogens. The inability
of these organisms to synthesize ATP obliges intracellular energy parasitism for
growth and replication. The species C. trachomatis causes 40-50 percent of NGU
[8-10,13]. Evidence linking C. trachomatis to NGU includes: significantly higher
isolation rates from patients with NGU compared to controls, serotype-specific IgM
antibody production in acute urethral infection, and resolution of urethritis after
eradication of the organism with antimicrobial therapy [8-10,13].
Diagnosis of C. trachomatis urethritis requires isolation of the organism in tissue
culture or detection of antibody production by microimmunofluorescence [34].
Since neither of these techniques are widely available, a presumptive diagnosis is
made by excluding GU with urethral Gram stain and culture. Compared to GU, C.
trachomatis urethritis is characterized by a longer incubation period [35], more
gradual symptom onset, clear or no discharge in greater than 90 percent ofcases [6],
and a link with higher socioeconomic status [19].
Complications of C. trachomatis urethritis in men include Reiter's syndrome in
1-2 percent [36,37], epididymitis in 3 percent, and prostatic involvement in 20-30
percent (largely asymptomatic) [7,13]. In addition, urethral stricture may result
from chronic C. trachomatis infection [7,16].
Serious consequences of C. trachomatis infection in women and neonates have
been identified. Chlamydia trachomatis can be recovered from the endocervix of
most female sexual contacts of men with C. trachomatis NGU [7,13]. Although in-
fection is largely asymptomatic, purulent cervicitis [38], cervical dysplasia [39],
pelvic inflammatory disease (PID) [40,41], perihepatitis [42,43], and the acute
urethral syndrome [44,45] maydevelop. Five percent ofwomen are estimated to har-
bor C. trachomatis, and recent data (culture and serology) implicate it as the cause
of 20-35 percent of PID in the U.S. [2,9].
Vertical transmission of C. trachomatis was first recognized in 1910 by Linder,
who demonstrated identical intracytoplasmic inclusions in maternal cervical scrap-
ings and conjunctival scrapings from neonates with inclusion conjunctivitis [46].
Screening data currently indicates that 10 percent of pregnant women have cervical
C. trachomatis infection [2]. Sixty to 70 percent of infants passing through an in-
fected birth canal become infected [47]. Manifestations ofneonatal infection include
acute follicular conjunctivitis, nasopharyngitis, serous otitis media, and infant
pneumonia [48,49]. Prospective observations have demonstrated that 35-50 percent
of exposed infants develop conjunctivitis and 10-20 percent develop pneumonia.
Vertically transmitted C. trachomatis is now recognized as the most common cause
of pneumonia in the first six months of life [47]. Furthermore, a tenfold greater in-
cidence of perinatal death has been reported in the offspring of C. trachomatis in-
fected women compared with uninfected controls [50].
The potential morbidity and mortality of C. trachomatis infection demand an ag-
gressive approach to the treatment and control of NGU.
Ureplasma urealyticum
Ureplasma urealyticum, formerly T-strain mycoplasma, is a minute coccobacillary
bacterium identified by its ability to hydrolize urea and form tiny, 15-30 Azm
diameter colonies on agar medium ("T" for tiny colonies). Whether U. urealyticum
114MALE URETHRITIS: DIAGNOSIS AND TREATMENT
is a cause of NGU remains unsettled [11]. The organism has been recovered more
frequently and in greater quantity (colony-forming units/ml) from men with non-
chlamydial NGU compared to asymptomatic controls [13,51,52]. However, isola-
tion rates from sexually active men without urethritis approach 65 percent [13]. It
has been postulated that only certain strains of U. urealyticum are pathogenic. The
report of urethritis developing in two investigators who inoculated themselves with
purified strains of U. urealyticum isolated from patients with NGU substantiates
this hypothesis [53]. Overall, evidence links U. urealyticum to 15-25 percent of
NGU [11,13].
No practical means are available to differentiate U. urealyticum from C. tracho-
matis urethritis. But, since both organisms are routinely sensitive to tetracycline and
erythromycin, differentiation is not required for initial therapy.
Other Causes ofNGU
Trichomonas vaginalis is a rare cause of male urethritis. In a consecutive series of
113 men with NGU, T. vaginalis was noted in the urine sediment ofonly one patient
[8]. Even when urethral infection occurs, it is largely asymptomatic [54,55]. Because
of its rarity, T. vaginalis need not be routinely considered in the initial evaluation
of men with urethritis. If suspicion is raised by known contact with vaginal
trichomoniasis, the motile protozoan can be detected with 80 percent sensitivity by
examination of the morning urine sediment. A culture of the urethral exudate or
urine sediment for trichomonas is indicated when microscopic examination is
negative and clinical suspicion remains high [56].
Herpes simplex, Candida albicans, and condylomata accuminata rarely, if ever,
cause urethritis without some extraurethral manifestation visible on the penis.
In 20-25 percent of NGU, no known pathogen can be recovered from the ure-
thra [8,13,14,57]. Culture-negative NGU occurs with greatest frequency among
homosexual and bisexual men. Recent data suggests that the causative agent is
tetracycline-suppressible. Bowie et al. demonstrated that 44 of46 patients with NGU
who had negative cultures for C. trachomatis and U. urealyticum responded to
minocycline therapy [14]. Although the initial response rate was excellent, over 50
percent of responders developed recurrent urethritis after cessation of treatment, in-
dicating that therapy was not always curative.
TREATMENT OF NGU
If polymorphonuclear leukocytes, but no intracellular Gram-negative diplococci
(GND) are present on urethral Gram stain, the presumptive diagnosis of NGU can
be made. Tetracycline 500 mg four times a day for seven days is the treatment of
choice. This regimen will also effectively treat the 10 percent ofgonococcal urethritis
in which urethral Gram stains are negative (intracellular GND absent). Chlamydia
trachomatis is uniformly tetracycline-sensitive, and tetracycline-resistant strains of
U. urealyticum are rare. As noted, the agent responsible for culture-negative NGU
also appears to be tetracycline-responsive. Collectively, these three agents account
for greater than 90 percent of NGU, which correlates with the 90 percent response
rate of NGU to tetracycline [58]. Spectinomycin and sulfonamides are less effective
for NGU because C. trachomatis is spectinomycin-resistant and U. urealyticum is
sulfonamide-resistant. Penicillin, ampicillin, and amoxicillin are ineffective, having
no activity against either C. trachomatis or U. urealyticum. The tetracycline
analogues, doxycycline 100 mg twice a day or minocycline 100 mg every day, can be
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substituted for four-times-a-day tetracycline, but expense is greater and a 15 percent
incidence of vestibular toxicity has been reported with minocycline [14]. All sexual
contacts of men with NGU should be treated with tetracycline (unless contraindi-
cated). For pregnant contacts, erythromycin 500 mg four times a day for seven days
should be substituted. Treatment of contacts will reduce reinfection of index cases,
eliminate carriers, and prevent the more serious manifestations of C. trachomatis in-
fection in women and infants. Asymptomatic C. trachomatis infection has been
documented to persist in women for over a year [59]. This chronic carrier state con-
stitutes the major source of horizontal and vertical C. trachomatis infection. Failure
to recognize and eradicate this reservoir has led to an epidemic of chlamydial dis-
eases in the U.S. [2].
PERSISTENT AND RECURRENT NGU
Despite proper treatment, persistent and recurrent NGU are common. In a recent
study of 289 men treated with minocycline for NGU, urethritis persisted on therapy
in 8 percent and recurred after completion of therapy in 22 percent. Combined per-
sistence and recurrent rates were 19 percent, 32 percent, and 52 percent for C.
trachomatis urethritis, U. urealyticum urethritis, and culture-negative urethritis,
respectively [14]. Little information exists on the proper management of persistent
or recurrent urethritis.
Urethritis that persists on tetracycline may result from infection with T. vaginalis
or a tetracycline-resistant strain of U. urealyticum. A saline mount of the urethral
exudate or morning urine sediment should be performed to detect trichomonads.
Whenever possible, the patient's sexual partner should be examined for vaginal
trichomoniasis. If trichomonads are detected in either partner, both should be
treated with metronidazole 2.0 g orally, in a single dose (contraindicated in preg-
nancy). When T. vaginalis is not detected, a seven-day course of erythromycin 500
mg four times a day is indicated for the possibility of tetracycline-resistant
ureaplasma infection [60].
Optimal management of recurrent NGU remains undefined. Extending initial
therapy beyond seven days does not prevent recurrences [14]. Reinfection from a
new or untreated sexual partner must always be excluded. If reinfection is possible,
retreatment of the patient and his contacts is warranted. Relapse from a persistent
nidus ofinfection within the prostate has also been postulated to be a cause ofrecur-
rent NGU. For this reason, erythromycin, which has better prostatic penetrance
than tetracycline, is recommended for recurrent NGU [16]. A dose of 500 mg four
times a day for one to two weeks should be prescribed.
For all cases of urethritis that persist unaffected by antibiotic therapy, cystoscopy
to exclude urethral stricture, diverticulum, or neoplasm is imperative.
SUMMARY APPROACH
Urethral PMNs must be detected to diagnose urethritis. IfPMNs and intracellular
Gram-negative diplococci (GND) are seen on urethral Gram stain, treatment of the
patient and his sexual contacts for gonorrhea is warranted. The choice of an-
tigonococcal therapy should depend on the likelihood ofmedication compliance and
the probability of antibiotic resistance or extragenital infection. Of the recommended
treatment regimens, only tetracycline will prevent postgonococcal urethritis. If
PMNs, but no intracellular GND are present on urethral Gram stain, treatment of
the patient and his sexual contacts with tetracycline or erythromycin for NGU is in-
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dicated. Differentiation between C. trachomatis, U. urealyticum, and culture-
negative urethritis is impractical and will not alter initial therapy. Regardless of the
initial treatment for GU or NGU, all patients should be reexamined after treatment
to document cure. Patients with persistent GU should be cultured and treated for
PPNG infection with spectinomycin. For persistent NGU, T. vaginalis infection
must be excluded. If trichomonas infection is not detected, erythromycin is in-
dicated for tetracycline-resistant ureaplasma infection. For recurrent NGU, retreat-
ment of the patient and his sexual partners with erythromycin for one to two weeks
is recommended. Urethritis unresponsive to antibiotic therapy should prompt an
anatomic evaluation of the urethra.
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